| abstract |
The present invention relates to immunomodulators. The present invention provides antibodies that specifically bind to PD-L1, fusion molecules comprising PD-L1 binding proteins constructed using IL15 receptor binding domains, nucleic acid molecules encoding the antibodies or fusion molecules, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cellular and cytokine-mediated immunity for the treatment of neoplastic and infectious diseases. |